Surmodics Inc SRDX
We take great care to ensure that the data presented and summarized in this overview for SURMODICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRDX
View all-
Black Rock Inc. New York, NY1.17MShares$48.7 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY887KShares$36.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA810KShares$33.7 Million0.0% of portfolio
-
Oddo Bhf Asset Management Sas Paris, I0610KShares$25.4 Million0.69% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT536KShares$22.3 Million0.06% of portfolio
-
Qube Research & Technologies LTD London, X0419KShares$17.4 Million0.01% of portfolio
-
Gabelli Funds LLC Rye, NY384KShares$16 Million0.09% of portfolio
-
Readystate Asset Management LP Chicago, IL383KShares$15.9 Million0.49% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il365KShares$15.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA339KShares$14.1 Million0.0% of portfolio
Latest Institutional Activity in SRDX
Top Purchases
Top Sells
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Insider Transactions at SRDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2025
|
Gordon S. Weber Sr. VP of Legal, GC and Sec. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,040
-100.0%
|
-
|
|
Nov 19
2025
|
John D. Manders VP Finance, Corp. Controller |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,155
-100.0%
|
-
|
|
Nov 19
2025
|
Charles W Olson SVP, Medical Device Coatings |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
800
-100.0%
|
-
|
|
Nov 19
2025
|
Charles W Olson SVP, Medical Device Coatings |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,478
-100.0%
|
-
|
|
Nov 19
2025
|
Susan E Knight |
SELL
Sale (or disposition) back to the issuer
|
Direct |
37,240
-100.0%
|
-
|
|
Nov 19
2025
|
Lisa Wipperman Heine |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,978
-100.0%
|
-
|
|
Nov 19
2025
|
David Dantzker |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,183
-100.0%
|
-
|
|
Nov 19
2025
|
Teri Woodwick Sides SVP, Vascular Interventions |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,703
-100.0%
|
-
|
|
Nov 19
2025
|
Joseph J. Stich SVP of HR, President IVD |
SELL
Sale (or disposition) back to the issuer
|
Direct |
61,631
-100.0%
|
-
|
|
Nov 19
2025
|
Timothy J. Arens Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,299
-100.0%
|
-
|
|
Nov 19
2025
|
Jose H Bedoya |
SELL
Sale (or disposition) back to the issuer
|
Direct |
30,008
-100.0%
|
-
|
|
Nov 19
2025
|
Gary R Maharaj President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
192,056
-100.0%
|
-
|
|
Feb 18
2025
|
Lisa Wipperman Heine |
SELL
Payment of exercise price or tax liability
|
Direct |
2,115
-13.14%
|
$71,910
$34.09 P/Share
|
|
Feb 18
2025
|
Lisa Wipperman Heine |
BUY
Exercise of conversion of derivative security
|
Direct |
2,640
+14.09%
|
$71,280
$27.3 P/Share
|
|
Feb 14
2025
|
Jose H Bedoya |
SELL
Payment of exercise price or tax liability
|
Direct |
4,224
-12.34%
|
$143,616
$34.1 P/Share
|
|
Feb 14
2025
|
Jose H Bedoya |
BUY
Exercise of conversion of derivative security
|
Direct |
5,275
+13.35%
|
$142,425
$27.3 P/Share
|
|
Feb 13
2025
|
David Dantzker |
SELL
Payment of exercise price or tax liability
|
Direct |
4,216
-9.5%
|
$143,344
$34.16 P/Share
|
|
Feb 13
2025
|
David Dantzker |
BUY
Exercise of conversion of derivative security
|
Direct |
5,275
+10.62%
|
$142,425
$27.3 P/Share
|
|
Jan 24
2025
|
Susan E Knight |
SELL
Payment of exercise price or tax liability
|
Direct |
5,266
-12.39%
|
$200,108
$38.15 P/Share
|
|
Jan 24
2025
|
Susan E Knight |
BUY
Exercise of conversion of derivative security
|
Direct |
7,358
+14.76%
|
$198,666
$27.3 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 20.5K shares |
|---|
| Sale (or disposition) back to the issuer | 559K shares |
|---|---|
| Payment of exercise price or tax liability | 39.3K shares |